NIPRADILOL

Details

Stereochemistry	UNKNOWN
Molecular Formula	C15H22N2O6
Molecular Weight	326.345
Optical Activity	UNSPECIFIED
Defined Stereocenters	0 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)NCC(O)COC1=C2OCC(CC2=CC=C1)O[N+]([O-])=O

InChI

InChIKey=OMCPLEZZPVJJIS-UHFFFAOYSA-N

InChI=1S/C15H22N2O6/c1-10(2)16-7-12(18)8-21-14-5-3-4-11-6-13(23-17(19)20)9-22-15(11)14/h3-5,10,12-13,16,18H,6-9H2,1-2H3

HIDE SMILES / InChI

Molecular Formula	C15H22N2O6
Molecular Weight	326.345
Charge	0
Count

Stereochemistry	MIXED
Additional Stereochemistry	No
Defined Stereocenters	0 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=1917
Curator's Comment: description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/11937782

Nipradilol is a beta blocker and nitric oxide donor. It was launched in Japan in 1988. This medicine lowers intraocular pressure by suppressing aqueous production and increasing fluid drainage from the eye. It is usually used to treat glaucoma and intraocular hypertension. The most commonly reported adverse reactions include conjunctival congestion, superficial keratitis, eye irritation, bloodshot eyes, itch and headache. If any of these symptoms occur, consult with your doctor or pharmacist.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Adrenergic receptor beta 87 Target ID: CHEMBL2094118 Sources: http://www.ncbi.nlm.nih.gov/pubmed/11937782	Antagonist 2778
Adrenergic receptor alpha-1 169 Target ID: CHEMBL2094251 Sources: http://www.ncbi.nlm.nih.gov/pubmed/11937782	Antagonist 2778

Conditions

Condition	Modality	Targets	Highest Phase	Product
Glaucoma 57 Sources: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=1917	Primary		Approved 8429	Unknown Approved Use Unknown
Ocular hypertension 50 Sources: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=1917	Primary		Approved 8429	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Nipradilol protects rat retinal ganglion cells from apoptosis induced by serum deprivation in vitro and by diabetes in vivo.	2008 Aug	18696344

Patents

Sample Use Guides

In Vivo Use Guide

1 drop at a time, twice a day.

Route of Administration: Other

In Vitro Use Guide

Nipradilol protects rat retinal ganglion cells from apoptosis induced by serum deprivation in vitro. Nipradilol protects RGCs from apoptosis

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:20:19 UTC 2023` Edited by `admin` on `Fri Dec 15 16:20:19 UTC 2023`
Record UNII	FVM336I71Y
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

NIPRADILOL

Official Name

English

nipradilol [INN]

Common Name

English

HYPADIL

Brand Name

English

Nipradolol [WHO-DD]

Common Name

English

NIPRADOLOL

Common Name

English

8-(2-HYDROXY-3-(ISOPROPYLAMINO)PROPOXY)-3-CHROMANOL, 3-NITRATE

Common Name

English

NIPRADILOL [INCI]

Common Name

English

NIPRADILOL [MI]

Common Name

English

NIPRADILOL [MART.]

Common Name

English

NIPRADILOL [JAN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29576